Heparin as an Anti-Inflammatory Agent
Authors:
- Leandar LitovLLLeandar Litov
- Peicho PetkovPPPeicho Petkov
- Miroslav RangelovMRMiroslav Rangelov
- Nevena IlievaNINevena Ilieva
- Elena LilkovaElena Lilkova
- Nadezhda TodorovaNadezhda Todorova
- Elena KrachmarovaElena Krachmarova
- Kristina MalinovaKMKristina Malinova
- Anastas GospodinovAGAnastas Gospodinov
- Rossitsa HristovaRHRossitsa Hristova
- Ivan IvanovIIIvan Ivanov
- Genoveva NachevaGNGenoveva Nacheva
Preprint
Abstract
Timely control of the cytokine release syndrome (CRS) at the severe stage of COVID-19 is key to improving the treatment success and reducing the mortality rate. The inhibition of the activity of the two key cytokines, IFNγ and IL-6, can significantly reduce or even reverse the development of the cytokine storm. The objective of our investigations is to reveal the anti-inflammatory potential of heparin for prevention and suppression of the development of CRS in acute COVID-19 patients. The effect of low-molecular-weight heparin (LMWH) on IFNγ signalling inside the stimulated WISH cells was investigated by measuring its antiproliferative activity and the translocation of phosphorylated STAT1 in the nucleus. The mechanism of heparin binding to IFNγ and IL-6 and therefore inhibition of their activity was studied by means of extensive molecular-dynamics simulations. We find that LMWH binds with high affinity to IFNγ and is able to inhibit fully the interaction with its cellular receptor. It also influences the biological activity of IL-6 by binding to either IL-6 or IL-6/IL-6Rα thus preventing the formation of the IL-6/IL-6Rα/gp130 signaling complex. Our conclusion is that heparin is a potent anti-inflammatory agent that can be used in acute inflammatory conditions, due to its potential to inhibit both IFN γ and IL-6 signalling pathways. Based on our results and available clinical observations, we suggest the administration of LMWH to COVID-19 patients in the initial stages of the acute phase. The beginning of the treatment and the dosage should be based on a careful follow-up of the platelet count and the D-dimer, IL-6, IFN, T-cells, and B-cells levels.Keywords
This publication has 85 references indexed in Scilit:
- UCSF Chimera, MODELLER, and IMP: An integrated modeling systemJournal of Structural Biology, 2012
- CHARMM Additive All-Atom Force Field for Carbohydrate Derivatives and Its Utility in Polysaccharide and Carbohydrate–Protein ModelingJournal of Chemical Theory and Computation, 2011
- Glycosaminoglycans mediate retention of the poxvirus type I interferon binding protein at the cell surface to locally block interferon antiviral responsesThe FASEB Journal, 2011
- GROMACS 4: Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular SimulationJournal of Chemical Theory and Computation, 2008
- Hepatitis B virus infection initiates with a large surface protein–dependent binding to heparan sulfate proteoglycansHepatology, 2007
- Canonical sampling through velocity rescalingThe Journal of Chemical Physics, 2007
- UCSF Chimera—A visualization system for exploratory research and analysisJournal of Computational Chemistry, 2004
- The Protein Data BankNucleic Acids Research, 2000
- Comparative Protein Modelling by Satisfaction of Spatial RestraintsJournal of Molecular Biology, 1993
- Molecular dynamics with coupling to an external bathThe Journal of Chemical Physics, 1984